4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike

August CPI rose 0.4% month over month and 3.4% year over year, while core CPI increased 0.3% versus 0.2% consensus, lifting market-implied odds of a 25bp Fed rate hike next week to 90%. Energy inflation intensified, with gasoline up 3.9% in August and energy prices up 16.3% year over year amid Middle East tensions. The article recommends defensive healthcare exposure through Amgen, Bausch Health, CareDx and Centene; CareDx and Centene are projected to deliver more than 100% current-year earnings growth, with consensus estimates revised up 35.2% and 40.9%, respectively, over 60 days.

Analysis

The defensiveness case is uneven. CNC has the cleanest macro insulation because revenue is tied to enrollment and state/federal rate-setting rather than discretionary utilization, but its real earnings variable is the medical-cost ratio: a weaker consumer can increase Medicaid enrollment while acuity and pharmacy costs erode the benefit. AMGN’s durable cash flows justify a lower-beta role, although a higher-for-longer rate regime can still cap multiple expansion for large-cap biopharma and intensify payer pressure on net pricing.

BHC should not be treated as a rate-defense proxy. Its leverage and refinancing sensitivity can dominate any resilient underlying demand; credit-spread widening would likely offset a modest improvement in operating estimates. CDNA is even less defensive: reimbursement coverage, transplant volumes, competitive assay adoption and cash burn matter far more than rates, making recent estimate revisions a weak standalone signal absent confirmation in revenue growth and gross-margin trajectory.

Over the next days, the policy decision is largely a positioning event rather than a differentiated healthcare catalyst. Over 1-3 months, state Medicaid rate notices, CNC utilization commentary, AMGN volume-versus-price trends, and BHC debt-market access are the relevant read-throughs. The contrarian view is that a growth slowdown may be more damaging to managed care than the headline suggests if states tighten reimbursement budgets with a lag; avoid paying a blanket "defensive" premium for the group.

The thesis fails if long-end yields and high-yield spreads fall materially after the policy event, favoring cyclicals and levered beta over healthcare quality; conversely, a sustained rise in high-yield spreads is a direct warning against BHC. For CNC, adverse medical-cost-ratio guidance or unfavorable state rate updates would invalidate the defensive earnings premise.

Key Decisions for Investors

• Prefer a 3-6 month long CNC / short BHC pair rather than outright healthcare exposure: CNC has more predictable funding and balance-sheet characteristics, while BHC embeds material credit sensitivity. Size modestly; exit if BHC credit spreads tighten decisively or CNC signals medical-cost-ratio deterioration.
• Use AMGN as the large-cap defensive allocation, but enter only on yield-driven weakness rather than chasing a macro-safety bid. Target a 6-12 month holding; reduce if product-level volume deceleration or net-price pressure causes forward EPS guidance to fall.
• Do not initiate CDNA solely on estimate revisions. Place it on a 1-2 quarter watchlist pending independently verifiable evidence of sustained testing-volume growth, reimbursement durability, improving gross margin, and sufficient liquidity runway.
• For a broad risk-off hedge over the next 1-3 months, favor long XLV versus short XLY rather than concentrated longs in BHC or CDNA; reassess if long-end Treasury yields decline and consumer-discretionary earnings revisions stabilize.